Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis"

被引：0
|
作者：
Giuliani, Jacopo [1 ]
Martelli, Salvatore [2 ]
Piacentini, Paolo [1 ]
Bonetti, Andrea [1 ]
机构：
[1] ASL 21 Reg Veneto, Dept Oncol, Mater Salutis Hosp, I-37045 Legnago Verona, Italy
[2] ASL 21 Reg Veneto, Dept Radiol, Mater Salutis Hosp, I-37045 Legnago Verona, Italy
来源：
TUMORI | 2015年 / 101卷 / 01期
关键词：
PLUS BEVACIZUMAB; POOLED ANALYSIS; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; THERAPY; EVENTS;
D O I：
10.5301/tj.5000258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E32 / E33
页数：2
相关论文
共 50 条
  • [1] Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    Tebbutt, N. C.
    Murphy, F.
    Zannino, D.
    Wilson, K.
    Cummins, M. M.
    Abdi, E.
    Strickland, A. H.
    Lowenthal, R. M.
    Marx, G.
    Karapetis, C.
    Shannon, J.
    Goldstein, D.
    Nayagam, S. S.
    Blum, R.
    Chantrill, L.
    Simes, R. J.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1834 - 1838
  • [2] Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Di Seri, Marisa
    Longo, Flavia
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Romiti, Adriana
    Barucca, Viola
    Adua, Daniela
    Tomao, Silverio
    FUTURE ONCOLOGY, 2012, 8 (09) : 1193 - 1197
  • [3] High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab
    Garde-Noguera, J.
    Gil-Raga, M.
    Evgenyeva, E.
    Garcia, J. A.
    Llombart-Cussac, A.
    Camps-Herrero, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (04): : 405 - 412
  • [4] Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Larsen, Finn Ole
    Boisen, Mogens Karsbol
    Fromm, Annelene L.
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2012, 51 (02) : 231 - 233
  • [5] Delayed anastomotic dehiscence in advanced colorectal cancer treated with Bevacizumab™
    Placer, Carlos
    Markinez, Izaskun
    Rodriguez, Araceli
    Luis Elosegui, Jose
    Enriquez Navascues, Jose Maria
    CIRUGIA ESPANOLA, 2010, 88 (04): : 267 - 268
  • [6] Interstitial Lung Disease During Chemotherapy Combined with Oxaliplatin and/or Bevacizumab in Advanced Colorectal Cancer Patients
    Usui, Kazuhiro
    Katou, Yuu
    Furushima, Kaoru
    Tanaka, Yoshiaki
    Tanai, Chiharu
    Ishihara, Teruo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (04) : 498 - 502
  • [7] Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
    Grothey, A
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 22 - 23
  • [8] Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis
    Deng, Jia
    Zeng, Xinglin
    Hu, Wenting
    Yue, Tinghui
    Luo, Zicheng
    Zeng, Lian
    Li, Ping
    Chen, Jiang
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38 (01)
  • [9] Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study
    Bar, Jair
    Spencer, Stuart
    Morgan, Shethah
    Brooks, Laura
    Cunningham, David
    Robertson, Jane
    Juergensmeier, Juliane M.
    Goss, Glenwood D.
    CLINICAL COLORECTAL CANCER, 2014, 13 (01) : 46 - 53
  • [10] Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy
    Peng, Yu
    Chen, Ye
    Zhang, Xi
    Yang, Yu
    Cao, Dan
    Bi, Feng
    Li, Zhipi
    Gou, Hongfeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1339 - 1346
12345